Korsana Biosciences, Inc. Common Stock
KRSA
34 hedge funds and large institutions have $18.3M invested in Korsana Biosciences, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 13 reducing their positions, and 4 closing their positions.
59% more capital invested
Capital invested by funds: $11.5M → $18.3M (+$6.79M)
0.74% more ownership
Funds ownership: 48.12% → 48.85% (+0.74%)
6% less funds holding
Funds holding: 36 → 34 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
69% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$108K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.31K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.24K |
| 4 |
Franklin Resources
San Mateo,
California
|
+$120 |
| 5 |
GAG
Goodman Advisory Group
Needham,
Massachusetts
|
+$52 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$32K |
| 2 |
Prudential Financial
Newark,
New Jersey
|
-$29K |
| 3 |
Renaissance Technologies
New York
|
-$21.2K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.7K |
| 5 |
Two Sigma Advisers
New York
|
-$7.39K |
KRSA Hedge Fund Activity: Q3 2022 in Review
34 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q3 2022, worth a combined $18.3M — up 59% from $11.5M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of KRSA and 2 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 4 added.
The largest buyer was Fidelity Investments, adding an estimated $108K. The largest seller was Jane Street, exiting entirely with an estimated $32K sold.
- 34 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q3 2022, down from 36 in Q2 2022.
- Funds reported $18.3M of Korsana Biosciences, Inc. Common Stock stock for Q3 2022, up 59% quarter-over-quarter.
- 2 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q3 2022 and 4 closed out, a net change of -2 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q3 2022 was Fidelity Investments, an estimated $108K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q3 2022 was Jane Street, an estimated $32K sold.
Based on aggregated 13F filings for Q3 2022.